Unique ID issued by UMIN | UMIN000015512 |
---|---|
Receipt number | R000017040 |
Scientific Title | The effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) on difficult to treat chough variant asthma (CVA). |
Date of disclosure of the study information | 2014/10/23 |
Last modified on | 2016/06/20 17:07:58 |
The effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) on difficult to treat chough variant asthma (CVA).
The effect of Ozagrel on difficult to treat cough variant asthma.
The effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) on difficult to treat chough variant asthma (CVA).
The effect of Ozagrel on difficult to treat cough variant asthma.
Japan |
cough variant asthma
Medicine in general | Adult |
Others
NO
To investigate the effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) add-on therapy to the patients persisting cough in spite of inhaled corticosteroid, long acting bronchodilator, and leukotriene receptor antagonist treatments.
Efficacy
Confirmatory
Not applicable
response of cough symptoms
1) Improvement of capsaicin cough sensitivity.
2)
Changes of Thromboxane B2 (TXB2)concentration in sputum.
Correlation between changes of TXB2 concentration and
a) Changes of scores in Leister cough questionnaire
b) Improvement of capsaicin cough sensitivity
c) Falling rate of sputum eosinophil count
d) Reduction rate of fractional exhaled nitric oxide and improvement of spirometry , Impulse Oscillation System.
e) Changes of MUC5AC concentration.
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
2
Treatment
Medicine |
Ozagrel
histamine H1 receptor antagonist
16 | years-old | <= |
Not applicable |
Male and Female
Cough variant asthma patients 16 years or older who are taking inhaled corticosteroid, long-acting bronchocilator, leukotriene receptor antagonist treatments.
1. Patients with suspicion of infectious disease such as pulmonary tuberculosis.
2. Current smoker, ex-smoker with smoking history within 6 months, ex-smoker with smoking history more than 5 pack-years.
3. Gastroesophageal reflux disease patients with scores of Frequency Scale for the Symptoms of GERD (FSSG) more than eight.
4. Patients with tendency to hemorrhages.
5.
Patients who takes histamine H1 receptor antagonist, anti-thromboxane agent, angiotensin converting enzyme inhibitor, or Non-Steroidal Anti-Inhlammatory Drugs.
30
1st name | |
Middle name | |
Last name | Akio Niimi |
Graduate School of Medical Sciences, Nagoya City University
Respiratory Medicine, Allergy and Clinical Immunology
1, kawasumi, mizuho-cho, mizuho-ku, Nagoya-city
052-851-5511
a.niimi@med.nagoya-cu.ac.jp
1st name | |
Middle name | |
Last name | Takamitsu Asano |
Graduate School of Medical Sciences, Nagoya City University
Respiratory Medicine, Allergy and Clinical Immunology
1, kawasumi, mizuho-cho, mizuho-ku, Nagoya-city
052-853-8077
t.asano@med.nagoya-cu.ac.jp
Graduate School of Medical Sciences, Nagoya City University
none
Other
NO
名古屋市立大学病院(愛知県)
2014 | Year | 10 | Month | 23 | Day |
Unpublished
Terminated
2014 | Year | 09 | Month | 24 | Day |
2014 | Year | 10 | Month | 22 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2014 | Year | 10 | Month | 23 | Day |
2016 | Year | 06 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017040
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |